Skip to content

Effect of Intensified Physical Activity for Patients With Stroke - a Combined Physical and Behavioural Approach

Description of Physical and Psychosocial Problems One Year After Stroke and the Effect of Intensified Physical Activity for Patients With Stroke - a Combined Physical and Behavioural Approach

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01161329
Enrollment
67
Registered
2010-07-13
Start date
2009-09-30
Completion date
2016-02-29
Last updated
2016-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

stroke, physical activity, balance, muscle-strength

Brief summary

Chronic conditions such as stroke are associated with physical disability and an economic burden for the family and the society. A medical approach is often not sufficient to address the bio-psychological process of chronic disease. Behavioural medicine approaches are often needed to improve the treatment outcomes. Those approaches have often successfully been used together with physical activity to change health behaviour in inactive individuals and in pain management. In this project the combined approach of behavioural medicine principles and physical training will be tried on patients who have had a stroke one year ago where it has yet only been used scarcely. As the study focus on the individuals' ability to function and be active the primary outcome measure is disability. The aim of the study are in a randomized controlled study evaluate if a high intense functional exercise program as an group intervention under three months can influence functional, psychosocial, anthropometric and biochemical factors 3, 6 months and 1 year after the start of the study. Following outcome variables will be analyzed: 1. level of physical activity, motor function and balance 2. depression and health-related quality of life 3. body mass index (BMI), metabolic risk profile, inflammation status 4. number of falls, fall-related self-efficacy and outcome expectations

Detailed description

Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.

Interventions

OTHERHigh-Intensity Functional Exercise Programmes (HIFE)

Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.

Sponsors

Uppsala County Council, Sweden
CollaboratorOTHER_GOV
Uppsala University Hospital
CollaboratorOTHER
Uppsala University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patient with first-ever stroke in the age of 65-65 years getting their stroke at least one year ago and living in the community.

Exclusion criteria

* Other illness or disability that have an impact on the activity level and participation in tests beside problems after stroke.

Design outcomes

Primary

MeasureTime frameDescription
The Berg Balance Scale (BBS)baseline, after 3, 6 months and after 1 yearTotal score on the scale: 0-56 Points. Higher scores indicates better balance.
Short Physical Performance Battery (SPPB)Baseline, after 3, 6 months and after 1 yearTotal score on the scale: 0-12 Points. Higher scores indicates better functioning. SPPB evaluates balance, gait, strength and endurance by examining an individual's ability to stand with feet together in side-by-side, semi-tandem and tandem positions, time to walk 8 ft and time to rise from a chair and return to the seated position five times.

Countries

Sweden

Participant flow

Recruitment details

A total of 195 individuals where screened for eligibility consecutively between October 2009 to April 2011.

Pre-assignment details

Of the 195 eligible participants 124 were ineligible and 4 declined participation..

Participants by arm

ArmCount
Controlgroup
Ordinary life.
33
Intervention Group
High Intensity Functional Exercise Program
34
Total67

Baseline characteristics

CharacteristicControlgroupIntervention GroupTotal
Age, Continuous73.7 years
STANDARD_DEVIATION 5.3
72.6 years
STANDARD_DEVIATION 5.5
73.1 years
STANDARD_DEVIATION 5.4
Months since stroke13 months13 months13 months
Region of Enrollment
Sweden
33 participants34 participants67 participants
Sex: Female, Male
Female
9 Participants7 Participants16 Participants
Sex: Female, Male
Male
24 Participants27 Participants51 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 330 / 34
serious
Total, serious adverse events
0 / 330 / 34

Outcome results

Primary

Short Physical Performance Battery (SPPB)

Total score on the scale: 0-12 Points. Higher scores indicates better functioning. SPPB evaluates balance, gait, strength and endurance by examining an individual's ability to stand with feet together in side-by-side, semi-tandem and tandem positions, time to walk 8 ft and time to rise from a chair and return to the seated position five times.

Time frame: Baseline, after 3, 6 months and after 1 year

ArmMeasureGroupValue (MEAN)Dispersion
ControlgroupShort Physical Performance Battery (SPPB)Mean SPPB change from baseline to 3 months0.15 units on a scaleStandard Deviation 1.1
ControlgroupShort Physical Performance Battery (SPPB)Mean SPPB change from baseline to 6 monnths0.4 units on a scaleStandard Deviation 1.8
ControlgroupShort Physical Performance Battery (SPPB)Mean SPPB change from baseline to 15 months0.7 units on a scaleStandard Deviation 2.4
Intervention GroupShort Physical Performance Battery (SPPB)Mean SPPB change from baseline to 3 months1.0 units on a scaleStandard Deviation 2.8
Intervention GroupShort Physical Performance Battery (SPPB)Mean SPPB change from baseline to 6 monnths0.9 units on a scaleStandard Deviation 2.7
Intervention GroupShort Physical Performance Battery (SPPB)Mean SPPB change from baseline to 15 months1.3 units on a scaleStandard Deviation 2.4
p-value: 0.09Wilcoxon (Mann-Whitney)
Primary

The Berg Balance Scale (BBS)

Total score on the scale: 0-56 Points. Higher scores indicates better balance.

Time frame: baseline, after 3, 6 months and after 1 year

ArmMeasureGroupValue (MEAN)Dispersion
ControlgroupThe Berg Balance Scale (BBS)BBS change from baseline to 15 months-0.6 units on a scaleStandard Deviation 3.4
ControlgroupThe Berg Balance Scale (BBS)BBS change from baseline to 3 months-0.06 units on a scaleStandard Deviation 2.8
ControlgroupThe Berg Balance Scale (BBS)BBS change from baseline to 6 months0.8 units on a scaleStandard Deviation 7.9
Intervention GroupThe Berg Balance Scale (BBS)BBS change from baseline to 6 months2.3 units on a scaleStandard Deviation 9.5
Intervention GroupThe Berg Balance Scale (BBS)BBS change from baseline to 3 months4.1 units on a scaleStandard Deviation 9.1
Intervention GroupThe Berg Balance Scale (BBS)BBS change from baseline to 15 months1.3 units on a scaleStandard Deviation 5.4
Comparison: Intention-to-treat analysis was performed to assess the effects on the outcome measures. Between-group differences for all outcome measures were analyzed using Mann-Whitney U-test.p-value: 0.001Wilcoxon (Mann-Whitney)

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026